General Information
Roche Diabetes 025
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar added to a Sulfonylurea or Added to a Sulfonylurea in Combination with Metformin in Patients with Type 2 Diabetes Mellitus (T2d) Inadequately Controlled with Sulfonylurea Monotherapy or with Sulfonylurea Plus Metformin Combination Therapy.
| Protocol | |
|---|---|
| Identifier | WC28325 |
| UID | dd2bf08b-8b41-433f-beff-67616b70c2ce |
| Status | Done - Archived |
| Phase | 3 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2012 |
| NCT Number | - |
| Created | 2012-09-06 17:14 |
| Last Updated | 2012-09-06 17:14 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2012-11-09 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2013-12-09 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Melendez, Jose | JMelendez | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Roche |
|---|---|
| Division | Roche |
| Team | Roche |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | 27474/2 |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
